CHRS — Coherus Oncology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1512762 ·
Last close
$0.48
Market Cap
$73.95M
52W High
$2.62
52W Low
$0.43
ADV30
2,183,633
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 14,307,000 | 10,065,000 | -32,331,000 | -20,631,000 | 191,183,000 | 82,923,000 | 130,345,000 |
| Mar 2026 | 12,310,000 | 8,496,000 | -36,151,000 | -38,327,000 | 266,022,000 | 115,238,000 | 187,399,000 |
| Dec 2025 | 12,748,000 | 8,703,000 | -45,880,000 | -37,643,000 | 258,343,000 | 88,879,000 | 197,329,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-173,711,000
Investing CF
$49,839,000
Financing CF
$73,861,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.97
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,481,261,000
Inventory
$4,824,000
Receivables
$13,916,000
ST Investments
$30,142,000
EBIT TTM
$-145,965,000
Pretax Income TTM
$-155,504,000
Interest Exp TTM
$9,539,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$53,639,000
EBITDA
$-141,919,008
Free Cash Flow
$-139,939,744
Enterprise Value
$67,129,864
Total Cash
$83,629,000
Total Debt
$69,549,000
Shares Out
154,538,277
Trailing EPS
$-1.12
Book Value
$0.16
ROE
-275.2%
ROA
-26.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 42,172,000 | -181,134,000 | 168,024,000 | 258,343,000 | 197,329,000 | 61,014,000 | -138,513,000 |
| Dec 2024 | 26,389,000 | -199,653,000 | 28,507,000 | 448,533,000 | 580,523,000 | -131,990,000 | -20,440,000 |
| Dec 2023 | 257,244,000 | -203,199,000 | -237,892,000 | 629,604,000 | 823,029,000 | -193,425,000 | -174,884,000 |
| Dec 2022 | 211,042,000 | -256,880,000 | -291,754,000 | 480,847,000 | 618,265,000 | -137,418,000 | -241,124,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$50,936,000
NetIncome TTM
$-132,132,000
OpCashFlow TTM
—
Assets (Latest)
$191,183,000
Forward EPS
$-0.63
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $0.50 · spot: $0.41 · call volume: 4 · put volume: 3
Expected Move to 2027-05-21:
±$0.34
(82.93%) —
implied range
$0.07 –
$0.75
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNYA | Tenaya Therapeutics, Inc. | $73.58M | $0.32 | — |
| CLLS | Cellectis S.A. | $77.08M | $1.06 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $68.60M | $0.74 | — |
| ATRA | Atara Biotherapeutics, Inc. | $66.22M | $6.50 | — |
| BDTX | Black Diamond Therapeutics, Inc. | $82.75M | $1.44 | — |
News headlines (Yahoo Finance, 1h cache)
Here's Why Coherus Oncology (CHRS) Is a Great 'Buy the Bottom' Stock Now
2026-11-18 13:55 · Yahoo
ONCY: Supply Agreement with Coherus to Evaluate Pelareorep in SCAC with Checkpoint Inhibitor
2026-11-16 13:05 · Yahoo
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC
2026-11-13 17:10 · Yahoo
Down 49.7% in 4 Weeks, Here's Why Coherus Oncology (CHRS) Looks Ripe for a Turnaround
2026-11-13 13:35 · Yahoo
Coherus Oncology Inc (CHRS) (Q3 2026) Earnings Call Highlights: Cost Cuts, Loqtorzi Growth and ...
2026-11-10 15:04 · Yahoo
Coherus Oncology, Inc. Q3 2026 Earnings Call Summary
2026-11-10 13:30 · Yahoo
Coherus Oncology: 3 Key Takeaways for Long-Term Investors
2026-11-10 08:10 · Yahoo
Coherus Oncology (CHRS) Q3 2026 Earnings Call Transcript
2026-11-10 07:48 · Yahoo
What Coherus Oncology (CHRS) Said on Its Q3 Earnings Call
2026-11-10 01:14 · Yahoo
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
2026-11-09 22:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.